StreetInsider.com News Articles

DiaMedica hits 200-patient mark in stroke trial, interim analysis due

Thu, 22 Oct 2026 08:00:27 -0400

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that the 200th patient has been enrolled in its Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) for acute ischemic stroke, triggering a pre-specified interim analysis by an independent Data Safety Monitoring Board (DSMB).

The DSMB will conduct its review after the 200th participant completes a 90-day follow-up period. The board will assess whether a sample size re-estimation is needed to optimize statistical power, or whether the trial should be stopped for futility. DiaMedica said it expects the interim analysis to be completed in the first quarter of 2027.

If the trial continues, the final participant

DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

Thu, 22 Oct 2026 08:00:00 -0400

Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation
Interim Analysis Results Expected in Q1 2027

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that the 200th patient has been enrolled in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in participants with acute ischemic stroke (AIS), reaching the prespecified enrollment threshold for the trial’s planned interim analysis.

Under the trial protocol, the interim analysis will be conducted by

DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

Thu, 22 Oct 2026 08:00:00 -0400

Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation
Interim Analysis Results Expected in Q1 2027

Under the trial protocol, the interim analysis will be conducted by

DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

Mon, 19 Oct 2026 08:00:00 -0400

Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026
Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time.

The new date will allow the Company to expand the presentation to include preliminary, interim

DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

Mon, 19 Oct 2026 08:00:00 -0400

Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026
Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke, today announced that its virtual key opinion leader (KOL) event, previously scheduled for October 23, 2026, will now be held on Tuesday, November 24, 2026, at 8:00am Eastern Time.

The new date will allow the Company to expand the presentation to include preliminary, interim

DiaMedica to present early Phase 2 FGR trial data at Oct. 23 webinar

Wed, 30 Sep 2026 08:30:18 -0400

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will host a virtual key opinion leader event on October 23, 2026, at 8:00 a.m. Eastern Time to present preliminary interim results from the first cohort of a Phase 2 investigator-sponsored trial evaluating DM199 (rinvecalinase alfa) for early-onset fetal growth restriction (FGR).

The webinar will feature four maternal-fetal medicine specialists: Professor Catherine Cluver of Stellenbosch University, Professor Stephen Tong and Professor Susan Walker of the University of Melbourne, and Professor Andrew Shennan of King's College London. Dr. Cluver, who serves as the trial's principal investigator, will present safety, tolerability, and preliminary findings from the first cohort.

According

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

Wed, 30 Sep 2026 08:30:00 -0400

Leading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa)
Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset FGR Trial to Be Presented

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am Eastern Time to discuss fetal growth restriction (FGR), the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

Wed, 30 Sep 2026 08:30:00 -0400

Leading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa)
Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset FGR Trial to Be Presented

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it will host a virtual key opinion leader (KOL) event on October 23, 2026 at 8:00am Eastern Time to discuss fetal growth restriction (FGR), the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment for

Form 4 DiaMedica Therapeutics For: Aug 10 Filed by: Pauls Dietrich John

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913309.html

Form 4 DiaMedica Therapeutics For: Aug 10 Filed by: Pauls Dietrich John

Wed, 12 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260812/26913309.html

Form S-8 DiaMedica Therapeutics

Tue, 11 Aug 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260811/26902256.html

Form S-8 DiaMedica Therapeutics

Tue, 11 Aug 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260811/26902256.html

DiaMedica Therapeutics Inc. (DMAC) Reports In-Line Q2 EPS

Mon, 10 Aug 2026 17:36:42 -0400

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.

Form 10-Q DiaMedica Therapeutics For: Jun 30

Mon, 10 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260810/26898650.html

Form 10-Q DiaMedica Therapeutics For: Jun 30

Mon, 10 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260810/26898650.html

Form 8-K DiaMedica Therapeutics For: Aug 10

Mon, 10 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260810/26898607.html

Form 8-K DiaMedica Therapeutics For: Aug 10

Mon, 10 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260810/26898607.html

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights